Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young children–United States, 2002

유아 및 어린이를 위한 다섯 번째 세포가 없는 백일해 백신의 식품의약국 승인 - 미국, 2002

Published on
Journal: Morbidity and Mortality Weekly Report
[저자] Centers for Disease Control and Prevention (CDC)
[Category] 백일해, 파상풍,
Pubmed URL    DOI URL    
[Source] pubmed

On May 14, 2002, the Food and Drug Administration (FDA) approved for use an additional combined diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (DAPTACEL Aventis Pasteur, Ltd. [Toronto, Ontario]) for the first 4 doses of the diphtheria and tetanus toxoids and pertussis vaccination (DTP) series administered to infants and children aged 6 weeks-6 years (before seventh birthday). DAPTACEL is the fifth acellular pertussis vaccine to be licensed for use among infants and young children in the United States. Of these five, three (Tripedia, Infanrix, and DAPTACEL) are distributed in the United States.

All Keywords